We focused on the STING and NF‐κB signaling pathways because STING activation is known to foster antitumor immunity by co‐regulating type I IFN and NF‐κB activation (Demaria et al, 2015; Yum et al, 2021; Zhang et al, 2022), which are enhanced in muTECs of melanoma‐bearing Atg5BECKO mice (Fig 3C and D). The gene discussed is NFKB1; the disease is melanoma.